DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Methemoglobinemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Nonmalignant Neoplasm

Intervention: chemotherapy (Drug); dapsone (Drug); medical chart review (Other); assessment of therapy complications (Procedure)

Phase: N/A

Status: Completed

Sponsored by: Vanderbilt-Ingram Cancer Center

Official(s) and/or principal investigator(s):
Adam J. Esbenshade, MD, Principal Investigator, Affiliation: Vanderbilt-Ingram Cancer Center

Summary

RATIONALE: Gathering information about how often methemoglobinemia occurs in young patients receiving dapsone for hematologic cancer or aplastic anemia may help doctors learn more about the disease and plan the best treatment. PURPOSE: This research study is looking at methemoglobinemia in young patients with hematologic cancer or aplastic anemia treated with dapsone.

Clinical Details

Official title: Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia

Study design: N/A

Primary outcome:

Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years

Major risk factors for developing methemoglobinemia

Detailed description: OBJECTIVES:

- Define the incidence of methemoglobinemia in patients with hematologic malignancy or

aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years.

- Identify major risk factors for developing methemoglobinemia.

OUTLINE: Medical charts are reviewed. Of particular interest is demographic information, reasons for beginning dapsone prophylaxis, duration of dapsone prophylaxis, dapsone dosing, methemoglobin level, and treatment with methylene blue.

Eligibility

Minimum age: N/A. Maximum age: 18 Years. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Diagnosis of hematologic malignancy or aplastic anemia

- Treated within the past 15 years with dapsone prophylaxis during treatment of

primary disease PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Locations and Contacts

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232-6838, United States

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee 37064, United States

Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: January 2009
Last updated: November 4, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017